The Society for Immunotherapy of Cancer has accepted two abstracts in relation to the trial of Alloplex’s lead technology platform, SUPLEXA, for presentation at this year’s 38th annual SITC meeting and conference. The posters to be presented by Dr. Rohit Joshi, alongside the Alloplex leadership team, are: We look forward to sharing the latest data…